Emil D. Kakkis - 01 Mar 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Reporting relationship: President & CEO, Director
Issuer ticker: RARE
Reported as of: 01 Mar 2026
Net transaction value: -$1,240,411
SEC form: 4
Accepted by SEC: 03 Mar 2026, 19:06:19 UTC
Prior SEC filing: 04 Mar 2025
Next SEC filing: 20 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Karah Parschauer, attorney-in-fact

Key filing fact

Emil D. Kakkis filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 03 Mar 2026.

Key facts

This page summarizes Emil D. Kakkis's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 19:06.

Change

Previous filing in this sequence was filed on 04 Mar 2025.
Current net transaction value: -$1,240,411.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001248093 Primary reporting owner

KAKKIS EMIL D

Relationship: President & CEO, Director
Address: C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO
Signature: /s/ Karah Parschauer, attorney-in-fact
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RARE transaction

Common Stock

Award

Transaction value: $0
Shares: +71,177
Change %: +11%
Price: $0.000000
Shares after: 712,908
Date: 01 Mar 2026
Ownership: Direct
Footnotes: F1

RARE transaction

Common Stock

Sale

Transaction value: $1,240,411
Shares: -54,404
Change %: -7.6%
Price: $22.80
Shares after: 658,994
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2, F3, F4, F5

RARE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,158,985
Date: 01 Mar 2026
Ownership: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Represents shares of common stock which previously granted performance stock units were converted on March 1, 2026 upon certification of the performance metrics.

Footnote F2

Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.54 to $23.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range

Footnote F4

Includes 490 shares acquired under the Company's Amended and Restated Employee Stock Purchase Plan on April 30, 2025.

Footnote F5

Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.